These findings demonstrate the direct role of BCR-ABL1 tyrosine kinase in suppressing TGF-β signaling in CML and explain how Imatinib-targeted therapy restored beneficial TGF-β anti-growth responses. The gene discussed is TGFB1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.